[1]陈晓炜 邵玉婷 耿劲松 陈钱.肿瘤新兴技术水平扫描报告分析及启示[J].中国卫生质量管理,2018,25(06):099-103.[doi:10.13912/j.cnki.chqm.2018.25.6.29]
点击复制

肿瘤新兴技术水平扫描报告分析及启示
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第25卷
期数:
2018年06期
页码:
099-103
栏目:
卫生技术评估专栏
出版日期:
2018-11-28

文章信息/Info

作者:
陈晓炜 邵玉婷 耿劲松 陈钱
南通大学医学院
关键词:
新兴技术; 肿瘤; 水平扫描; 临床研究证据; 经济学评价
Keywords:
Emerging Technology;  Tumor;  Horizon Scanning;  Evidence of Clinical Research; Economic Evaluation
DOI:
10.13912/j.cnki.chqm.2018.25.6.29
摘要:
目的系统分析EuroScan发布的肿瘤新兴技术水平扫描报告，为我国新兴卫生技术评估提供借鉴。方法明确检索词获取EuroScan 2013年1月1日-2017年5月31日发布的肿瘤新兴技术水平扫描报告，制定报告的纳入及排除标准，设计资料提取表提取信息，对纳入报告进行描述性分析。结果纳入293份报告，其中241份针对药品，52份针对器械和其他诊疗技术。技术接受水平扫描的最主要原因是可为患者提供额外或新的备选诊疗方案，扫描过程中需要基于多维度的信息对技术影响进行分析和预测。结论肿瘤新兴技术水平扫描工作由专业机构在技术生命周期早期开展，从多个维度对技术进行早期评估。建议构建国家级本土化新兴卫生技术水平扫描系统，加强国际合作网络建设，促进国际机构间合作交流，公开报告，确保新兴技术各维度信息可追溯，为新兴卫生技术的准入和推广应用提供决策支持。
Abstract:
ObjectiveTo provide suggestions for the assessment of emerging health technologies in China through systematic analyzing the reports of emerging cancer technologies horizon scanning published by EuroScan.MethodsSearch terms were developed, and the horizon scanning reports for emerging tumor technologies published from January 1, 2013 to May 31, 2017 were retrieved. Inclusion and exclusion criteria were developed, and the data extraction table was designed to collect information. Descriptive analysis was used to investigate the included reports.ResultsTwo hundred and ninety-three reports were included, of which two hundred and forty-one for drugs and fifty-two for instruments and other types of medical techniques. The commonest reasons for horizon scanning were to provide additional or new alternative therapy for patients. During the scanning procedure, the impact of emerging technologies was analyzed and predicted on the basis of multi-dimensional information.Conclusion Emerging cancer technologies were scanned by professional organizations at early stage of the technical life cycle, and the technologies were evaluated early from several dimensions. Horizon scanning system should be established to identify, track, integrate and update multi-dimensional information of emerging health technologies, thus providing decision support for the access and diffusion of emerging health technologies.

参考文献/References:

［1］夏志远, 周萍, 刘亦悦,等. 国际新兴卫生技术评估经验及启示［J］.中国卫生质量管理,2016,23(1):91-95.

相似文献/References:

[1]林伟龙邓明梁锌甘蓝霞杨娟王惠杨谨成杨文静.2017年-2019年我国三级公立医院肿瘤住院患者医疗服务与质量安全分析[J].中国卫生质量管理,2022,29(11):001.[doi:10.13912/j.cnki.chqm.2022.29.11.01 ]
　LIN Weilong,DENG Ming,LIANG Xin.Analysis on Medical Service and Quality Safety of Tumor Inpatients in Chinese Tertiary Public Hospitals from 2017 to 2019[J].Chinese Health Quality Management,2022,29(06):001.[doi:10.13912/j.cnki.chqm.2022.29.11.01 ]
[2]邓明时黎明林伟龙杨谨成安宇杨娟周成诚杨文静.我国肿瘤单病种质控路径实践与展望[J].中国卫生质量管理,2022,29(11):006.[doi:10.13912/j.cnki.chqm.2022.29.11.02 ]
　DENG Ming,SHI Liming,LIN Weilong.Practice and Prospect of Quality Control Path of Single Disease of Tumor in China[J].Chinese Health Quality Management,2022,29(06):006.[doi:10.13912/j.cnki.chqm.2022.29.11.02 ]
[3]邓明林伟龙安宇杨娟杨文静.关于肿瘤治疗前临床TNM分期评估的思考[J].中国卫生质量管理,2022,29(11):009.[doi:10.13912/j.cnki.chqm.2022.29.11.03 ]
　DENG Ming,LIN Weilong,AN Yu.Consideration on Clinical TNM Stage Evaluation before Tumor Treatment[J].Chinese Health Quality Management,2022,29(06):009.[doi:10.13912/j.cnki.chqm.2022.29.11.03 ]
[4]林伟龙王惠杨文静.我国肿瘤专业医疗质量控制中心建设现状调查[J].中国卫生质量管理,2024,31(02):035.[doi:10.13912/j.cnki.chqm.2024.31.2.09]
　LIN Weilong,WANG Hui,YANG Wenjing.The Construction of Tumor Professional Medical Quality Control Center in China: a Cross-Sectional Study[J].Chinese Health Quality Management,2024,31(06):035.[doi:10.13912/j.cnki.chqm.2024.31.2.09]
[5]周成诚 杨娟 杨谨成 时黎明 安宇 王惠 郑苏菲 杨文静.我国肺癌多学科诊疗建设现状调查研究[J].中国卫生质量管理,2024,31(11):035.[doi:10.13912/j.cnki.chqm.2024.31.11.08]
　ZHOU Chengcheng,YANG Juan,Yang Jincheng.Investigation on the Current Situation of Multi-Disciplinary Treatment of Lung Cancer in China[J].Chinese Health Quality Management,2024,31(06):035.[doi:10.13912/j.cnki.chqm.2024.31.11.08]
[6]饶少锋 江波涛 杨岳利 陆凡 殷平平 陈成.肿瘤治疗前临床TNM分期评估的影响因素分析[J].中国卫生质量管理,2025,32(01):043.[doi:10.13912/j.cnki.chqm.2025.32.1.10]
　RAO Shaofeng,JIANG Botao,YANG Yueli.Analysis of Influencing Factors in Clinical TNM Staging Evaluation before Treatment of Tumor[J].Chinese Health Quality Management,2025,32(06):043.[doi:10.13912/j.cnki.chqm.2025.32.1.10]

更新日期/Last Update: 2018-11-28